Ironwood Pharmaceuticals ... (IRWD)

NASDAQ: IRWD · Real-Time Price · USD

0.93

-0.00 (-0.25%)

At close: May 01, 2025, 3:58 PM

-0.25% (1D)

Bid	0.92
Market Cap	149.79M
Revenue (ttm)	351.41M
Net Income (ttm)	29.26M
EPS (ttm)	0.01
PE Ratio (ttm)	92.57
Forward PE	4.25
Analyst	Hold

Ask	0.93
Volume	1,096,412
Avg. Volume (20D)	3,920,137
Open	0.95
Previous Close	0.93
Day's Range	0.88 - 0.95
52-Week Range	0.59 - 8.45
Beta	0.30

About IRWD

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European...

Sector Healthcare

IPO Date Feb 3, 2010

Employees 253

Stock Exchange NASDAQ

Ticker Symbol IRWD

Website https://www.ironwoodpharma.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for IRWD stock is "Hold." The 12-month stock price forecast is $1, which is an increase of 8.03% from the latest price.

Stock Forecasts

Next Earnings Release

Ironwood Pharmaceuticals Inc. is scheduled to release its earnings on May 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

-31.48%

Ironwood Pharmaceuticals shares are trading lower ... Unlock content with Pro Subscription

3 months ago

-38.17%

Ironwood Pharmaceuticals shares are trading lower. The company board announced approval for a 50% reduction in the workforce.

News

8 hours ago · zacks.com

Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 day ago · businesswire.com

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7t...

6 days ago · businesswire.com

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and ...

1 week ago · businesswire.com

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and r...

2 weeks ago · zacks.com

Ironwood Shares Tank on Regulatory Update for Apraglutide

Per the latest discussion with the FDA, a confirmatory phase III study is required to seek approval for IRWD's apraglutide in short bowel syndrome with intestinal failure.

2 weeks ago · benzinga.com

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug

Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intest...

2 weeks ago · businesswire.com

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

2 weeks ago · seekingalpha.com

Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth

Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZE...

3 weeks ago · reuters.com

Google launches new Ironwood chip to speed AI applications

Alphabet's on Wednesday unveiled its seventh-generation artificial intelligence chip named Ironwood, which the company said is designed to speed the performance of AI applications.

1 month ago · businesswire.com

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (the “Company”) (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointe...

Load More News